NASDAQ:HOWL Werewolf Therapeutics Q4 2024 Earnings Results & Report $0.98 -0.01 (-0.72%) As of 09:54 AM Eastern This is a fair market value price provided by Massive. Learn more. Werewolf Therapeutics missed analyst earnings expectations in its Q4 2024 results, released March 11, 2025. The company reported EPS of -$0.46 versus the -$0.43 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 11, 2025TimeBefore Market OpensConference Call7:00 AM ET Werewolf Therapeutics EPS ResultsActual EPS-$0.46Consensus EPS -$0.43Beat/MissMissed by -$0.03One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersWerewolf Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.00 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsWerewolf Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Friday, October 30, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Werewolf Therapeutics Q4 2024 Earnings FAQ Did Werewolf Therapeutics beat earnings estimates for Q4 2024? Werewolf Therapeutics (NASDAQ:HOWL) reported earnings of -$0.46 per share for Q4 2024, missing the consensus estimate of -$0.43. The report was announced on Tuesday, March 11, 2025. When is Werewolf Therapeutics' next earnings date? Werewolf Therapeutics' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Werewolf Therapeutics on the company's earnings history page. Werewolf Therapeutics Earnings HeadlinesWerewolf Therapeutics (NASDAQ:HOWL) Raised to "Strong-Buy" at Zacks ResearchOctober 7, 2026 | americanbankingnews.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)September 24, 2026 | globenewswire.comRent out your stocks?If you owned a rental house, you would collect rent while you waited for it to rise in value. A covered call lets you do something similar with stocks you already own. Own at least 100 shares and you can get paid cash today for agreeing to sell them at a higher price later. That cash is yours to keep no matter what happens next. Bill Poulos breaks it down in The Retirement Paycheck Playbook, normally $29.97, free today.October 14 at 1:00 AM | Profits Run (Ad)BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)September 9, 2026 | globenewswire.comWerewolf Therapeutics Completes Key Early Trial For WTX-124 In Hard-To-Treat CancersAugust 27, 2026 | tipranks.com1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding BoostAugust 26, 2026 | finance.yahoo.comSee More Werewolf Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Werewolf Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Werewolf Therapeutics and other key companies, straight to your email. Email Address About Werewolf TherapeuticsWerewolf Therapeutics (NASDAQ:HOWL) is a clinical-stage biopharmaceutical company focused on developing investigational cancer immunotherapies. The company’s programs are designed to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues, with the goal of improving the effectiveness and tolerability of immune-based treatments. Werewolf’s research is based on its proprietary INDUKINE platform, which uses molecular masking and tumor-activated mechanisms to conditionally regulate immune-stimulating proteins. Its pipeline has included engineered cytokine therapies such as WTX-124, an investigational systemic interleukin-2 therapy, and WTX-330, an investigational interleukin-12 therapy. These programs are being developed for potential use across a range of solid tumors and may be evaluated alone or in combination with other cancer treatments. Founded in 2017 and headquartered in the United States, Werewolf Therapeutics does not market approved commercial products and is focused primarily on research, clinical development and collaborations related to its immunotherapy platform. As a development-stage biotechnology company, its programs remain subject to clinical, regulatory and manufacturing requirements before they can potentially reach patients.View Werewolf Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
